All Updates

All Updates

icon
Filter
Funding
MiroBio raises USD 97 million in Series B funding round
Precision Medicine
Jun 29, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Precision Medicine

Precision Medicine

Jun 29, 2022

MiroBio raises USD 97 million in Series B funding round

Funding

  • UK-based clinical-stage biotechnology startup MiroBio has raised USD 97 million (GBP 80 million) in a Series B funding round led by Medicxi, with participation from several other new and existing investors including OrbiMed. Nick Williams of Medicxi and Erez Chimovits of OrbiMed will join MiroBio’s board of directors.

  • The funds will be used to progress its lead antibody drug candidates, MB272 and MB151 into clinical trials. The MB272 and MB151 candidates are checkpoint receptor agonists for treating autoimmune diseases. The funds will also be directed toward advancing its preclinical pipeline and building out its proprietary I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium) discovery platform.

  • MiroBio’s I-ReSToRE platform was designed to help discover and develop treatment strategies for autoimmune diseases, based on an atlas of receptor expressions and functions, antibody discovery processes, and advanced bioinformatics. The firm’s technology was built on more than 15 years of checkpoint agonism research at the University of Oxford.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.